Influence of nintedanib on pulmonary function, pulmonary fibrosis degree and serum PDGF, PGE2 and TGF-&#x03B2;1 levels in patients with idiopathic pulmonary fibrosis

doi:10.3877/cma.j.issn.1674-6902.2024.03.005

Abstract

Abstract:

Objective

To analyze the influence of nintedanib on pulmonary function, pulmonary fibrosis degree, serum platelet-derived growth factor (PDGF), prostaglandin E2 (PGE2), and serum transforming growth factor-β1 (TGF-β1) in patients with idiopathic pulmonary fibrosis (IPF).

Methods

152 patients with IPF in the hospital were selected as the subjects from March 2019 to March 2023. 65 patients who were treated with routine treatment + pirfenidone were included in control group, and 87 patients who received nintedanib based on routine treatment were enrolled as observation group. The clinical efficacy and adverse reactions after treatment and pulmonary function indicators, vascular endothelial function indicators, pulmonary fibrosis degree and pro-fibrosis-related factors before and after treatment were compared between both groups.

Results

After treatment, the total effective rate in observation group was higher than that in control group [85 cases(97.7%) vs. 58 cases(89.2%)] (P<0.05). There were no statistical differences in the adverse reactions between groups (P>0.05). The pulmonary function indicators and endothelial nitric oxide (NO) in both groups were enhanced after treatment than those before treatment, and FEV₁[(2.05±0.23) vs. (1.88±0.27)]L, FVC[(2.14±0.21) vs. (1.93±0.27)]L, DL_CO[(16.19±1.51) vs. (14.84±1.73)]ml/min·mmHg and NO[(825.10±98.37) vs. (746.01±77.78)]nmol/L were higher in observation group than those in control group (P<0.05). The pulmonary fibrosis degree, endothelin-1 (ET-1) and pro-fibrosis-related factors were reduced in the two groups compared with those before treatment, and Ⅳ C [(89.25±12.23) vs. (95.58±14.54)]ng/ml, HA[(185.44±23.01) vs. (197.23±27.17)]ng/ml, chest CT imaging score[(1.56±0.18) vs. (1.70±0.20)] points, ET-1[(57.78±10.05) vs. (70.14±10.53)]ng/L, PDGF[(136.85±61.07) vs. (217.47±67.12)] ng/L, PGE2[(258.57±50.28) vs. (329.28±71.43)]ng/L and TGF-β1 [(159.41±115.91) vs. (236.92±137.89)]ng/L in observation group were lower compared to control group (P<0.05).

Conclusion

Nintedanib can effectively treat IPF, improve pulmonary function, vascular endothelial function indicators and pulmonary fibrosis degree, and reduce the levels of pro-fibrosis-related factors.

Key words: Nintedanib, Idiopathic pulmonary fibrosis, Pulmonary function, Pulmonary fibrosis degree, Serum prostaglandin E2, Transforming growth factor -β1

Xuan Zhou, Li Xie, Juan Zou. Influence of nintedanib on pulmonary function, pulmonary fibrosis degree and serum PDGF, PGE2 and TGF-β1 levels in patients with idiopathic pulmonary fibrosis[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 368-372.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2024.03.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2024/V17/I03/368

Figures/Tables 4

References 29

1	胡　琴，刘田田，许朋俐，等. 基于线粒体自噬的特发性肺纤维化发病机制和药物干预的探讨[J]. 生理科学进展，2023, 54(1): 52-56.
2	于　娜，周家为，李　霞，等. 成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读[J]. 中国现代医学杂志，2023, 33(14): 1-8.
3	孙　晖，任　莉，胡静星，等. Ⅳ型胶原蛋白、Ⅲ型前胶原氨基端肽与老年特发性肺纤维化病人肺功能和急性加重的相关性[J]. 实用老年医学，2023, 37(9): 929-933.
4	Strykowski R, Adegunsoye A. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis[J]. Immunol Allergy Clin North Am, 2023, 43(2): 209-228.
5	魏会强，侯彦琨，郝秀玲，等. Bcl-2-like 11基因多态性与肺间质纤维化肺功能和肺部感染的关联[J]. 中华医院感染学杂志，2023, 33(6): 826-830.
6	Glass DS, Grossfeld D, Renna HA, et al. Idiopathic pulmonary fibrosis: Current and future treatment[J]. Clin Respir J, 2022, 16(2): 84-96.
7	Ghazipura M, Mammen MJ, Bissell BD, et al. Pirfenidone in progressive pulmonary fibrosis: A systematic review and Meta-analysis[J]. Ann Am Thorac Soc, 2022, 19(6): 1030-1039.
8	王　帅，王亚文，邹永祎，等. 尼达尼布治疗特发性肺纤维化92例对肺功能和肺纤维化指标的影响及不良反应分析[J]. 安徽医药，2023, 27(4): 826-829.
9	中华医学会呼吸病学分会间质性肺疾病学组. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志，2016, 39(6): 427-432.
10	Tabatabaei MS, Ahmed M. Enzyme-linked immunosorbent assay (ELISA)[J]. Methods Mol Biol, 2022, 2508: 115-134.
11	中华医学会病理学分会胸部疾病学组. 中国特发性肺纤维化临床-影像-病理诊断规范[J]. 中华病理学杂志，2018, 47(2): 81-86.
12	孙宇新，黄　慧. 尼达尼布联合吡非尼酮治疗特发性肺纤维化的INJOURNEY研究[J]. 中华结核和呼吸杂志，2018, 41(5): 339.
13	Munchel JK, Shea BS. Diagnosis and management of idiopathic pulmonary fibrosis[J]. R I Med J (2013), 2021, 104(7): 26-29.
14	许　娟，张党锋. 尼达尼布对肺纤维化小鼠肺功能及内质网应激反应的影响[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(5): 673-675.
15	Pan L, Cheng Y, Yang W, et al. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating PI3K/Akt/mTOR pathway in mice[J]. Inflammation, 2023, 46(4): 1531-1542.
16	Otsubo K, Kishimoto J, Ando M, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial[J]. Eur Respir J, 2022, 60(6): 2200380.
17	Jamadar A, Suma SM, Mathew S, et al. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease[J]. Cell Death Dis, 2021, 12(10): 947.
18	Wijsenbeek M, Swigris JJ, Inoue Y, et al. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis[J]. Eur Respir J, 2024, 63(2): 2300752.
19	丁　旻，李佳旻，洪群英，等. 尼达尼布治疗特发性肺纤维化的长期疗效及安全性：单中心参与INPULSIS及INPULSIS ON的系列病例分析[J]. 复旦学报(医学版), 2022, 49(3): 395-401.
20	Pulito-Cueto V, Genre F, López-Mejías R, et al. Endothelin-1 as a Biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases[J]. Int J Mol Sci, 2023, 24(2): 1275.
21	李怡华，叶　俏. 抗肺纤维化药物尼达尼布和吡非尼酮临床试验进展[J]. 中华劳动卫生职业病杂志，2020, 38(1): 62-65.
22	李海娜，刘　畅，王金柱，等. 尼达尼布联合参附注射液对百草枯中毒大鼠肺损伤的保护作用[J]. 中华劳动卫生职业病杂志，2023, 41(2): 81-86.
23	Li X, Xi B, Miao Y, et al. Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling[J]. Int Immunopharmacol, 2021, 100: 108129.
24	Liu F, Yu C, Qin H, et al. Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial-to-mesenchymal transition, inflammation and angiogenesis[J]. J Cell Mol Med, 2021, 25(13): 6103-6114.
25	张　秀，杨三春. 尼达尼布对肺纤维化患者内皮素-1、血管紧张素的影响[J]. 临床输血与检验，2020, 22(1): 68-71.
26	Chen R, Dai J. Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy[J]. J Mol Med (Berl), 2023, 101(8): 905-915.
27	邓　泽，戢新平. 吡非尼酮联合尼达尼布治疗特发性肺纤维化患者的临床研究[J]. 中国临床药理学杂志，2022, 38(11): 1174-1176, 1194.
28	黄晓娜，李　龙，赵　华. 前列腺素E 2在特发性肺纤维化中的作用[J]. 国际呼吸杂志，2022, 42(8): 623-629.
29	李佳怡，王亚菲，郝月琴，等. CXCL14、TGF-β1和CTGF水平与特发性肺纤维化的关系[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 222-224.

组　别	例数	FEV₁(L)		FVC(L)		DL_CO[ml/(min·mmHg)]
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	87	0.94±0.15	2.05±0.23^a	1.16±0.19	2.14±0.21^a	10.14±1.37	16.19±1.51^a
对照组	65	0.92±0.17	1.88±0.27^a	1.09±0.20	1.93±0.27^a	10.19±1.30	14.84±1.73^a
t值		0.768	4.183	0.536	5.394	0.227	5.122
P值		0.443	0.000	0.592	0.000	0.820	0.000

组　别	例数	FEV₁(L)		FVC(L)		DL_CO[ml/(min·mmHg)]
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	87	0.94±0.15	2.05±0.23^a	1.16±0.19	2.14±0.21^a	10.14±1.37	16.19±1.51^a
对照组	65	0.92±0.17	1.88±0.27^a	1.09±0.20	1.93±0.27^a	10.19±1.30	14.84±1.73^a
t值		0.768	4.183	0.536	5.394	0.227	5.122
P值		0.443	0.000	0.592	0.000	0.820	0.000

组　别	例数	ET-1(ng/L)		NO(nmol/L)
组　别	例数	治疗前	治疗后	治疗前	治疗后
观察组	87	94.32±11.98	57.78±10.05^a	419.03±44.79	825.10±98.37^a
对照组	65	93.89±12.14	70.14±10.53^a	417.88±45.24	746.01±77.78^a
t值		0.218	7.350	0.156	5.350
P值		0.828	0.000	0.876	0.000

组　别	例数	ET-1(ng/L)		NO(nmol/L)
组　别	例数	治疗前	治疗后	治疗前	治疗后
观察组	87	94.32±11.98	57.78±10.05^a	419.03±44.79	825.10±98.37^a
对照组	65	93.89±12.14	70.14±10.53^a	417.88±45.24	746.01±77.78^a
t值		0.218	7.350	0.156	5.350
P值		0.828	0.000	0.876	0.000

组　别	例数	Ⅳ C(ng/ml)		HA(ng/ml)		胸部CT影像学评分(分)
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	87	111.40±15.63	89.25±12.23^a	225.16±35.89	185.44±23.01^a	2.95±0.26	1.56±0.18^a
对照组	65	110.89±16.07	95.58±14.54^a	224.89±36.00	197.23±27.17^a	2.91±0.25	1.70±0.20^a
t值		0.197	2.911	0.046	2.892	0.854	4.523
P值		0.844	0.004	0.963	0.004	0.342	0.000

Please choose a citation manager

Content to export

Influence of nintedanib on pulmonary function, pulmonary fibrosis degree and serum PDGF, PGE2 and TGF-β1 levels in patients with idiopathic pulmonary fibrosis

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 29

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Maoxian Yang, Peng Shen, Qianqian Wang, Wang Wu, Yongshuai Shen, Zhen Jiang, Longsheng Xu, Jiangang Zhu, Beibei Liu. Therapeutic effect of magnesium picolinate and dexamethasone on acute respiratory distress syndrome rats [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(03): 196-203.
[2]	Yueting Wu, Linyuhan Zhou, Qin Hu, Huayan Xu, Min Huang, Xiaoyong Chen, Meng Zhang, Zhonghui Li, Liang Ru, Qiu Wang, Xiaotang Cai. Longitudinal study of pulmonary and motor function in children with ambulatory Duchenne muscular dystrophy treated with corticosteroids [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 292-301.
[3]	Anqi Li, Yilin Xu, Tianxin Xiang. Progress on diagnosis and treatment of post corona virus disease 2019 pulmonary fibrosis [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 294-298.
[4]	Dongli Chen, Yingli Deng, Jing Bi. Effects of alpha-interferon on Th1/Th2 and lung function in the treatment of acute respiratory virus infection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 590-594.
[5]	Lingxiao Qiu, Chuangye Wang, Bin Qing, Jincheng Liu, Xinye Zhang, Wenjuan Wu, Debing Xing, Liang Guo, Zhi Xu, Bin Wang. Identifying hub genes and pathways in idiopathic pulmonary fibrosis based on transcriptomics [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(02): 212-217.
[6]	Enzhu Zhou, min Liu, Qiu Wan, Jingwen Liu, Lixin Tang. Clinical characteristics of acquired immunodeficiency syndrome complicated with chronic obstructive pulmonary disease [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 78-82.
[7]	Cuomao Lazhou, Chunling Shan, Guorong Li, Mao Hua. Pathological types and clinical characteristics of IPF-LC patients in Xining [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 25-29.
[8]	Jiamin Liu, Xiao Xie, Mei Li. Efficacy of fiberoptic bronchoscopy combined with ambroxol in the treatment of COPD with respiratory failure and its effects on blood gas indicators, pulmonary function and blood lactate level [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(05): 640-644.
[9]	Juan Zou, Yuqing Liu, Yuanyuan Wan. Efficacy of BiPAP non-invasive ventilator in the treatment and cure of acute exacerbation of pulmonary heart disease and its effects on serum NT-proBNP, arterial blood gas indicators and pulmonary function [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 6-10.
[10]	Xizhong Sui, Chengyu Huo. The contrastive study on pulmonary function of small airway changes between segmentectomy and wedge resection [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2022, 15(03): 168-173.
[11]	Ke Zhang, Erming Zhang, Wei Yan, Shitou Ma, Xinhua An, Caoxin Bao, Pingchao Xiang. Correlation between lung function and smoking status in patients with preserved-ratio impaired spirometry and chronic obstructive pulmonary disease over 40 years of age in Shijingshan district of Beijing [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 122-127.
[12]	Ze Deng, Xinping Ji. Effect of pulmonary rehabilitation chronic disease management mode on pulmonary function, quality of life, and prognosis in patients with mild to moderate asthma-chronic obstructive pulmonary disease overlap syndrome [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 937-943.
[13]	Kunming Lv, Shasha Wang, Jun Wan, Enqiang Linghu. Research progress on the relationship between gastroesophageal reflux disease and idiopathic pulmonary fibrosis [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(02): 121-124.
[14]	Zekai Zhou, Baoyin Liu, Yuntao Nie, Hua Meng. Research progress in the effects of obesity on lung function [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(01): 58-65.
[15]	Ling Yang, Hongyan Yu, Jie Zhang, Guoyu Jia, Ying Li, Fusheng Di. Characteristics of cardiopulmonary function during exercise in type 2 diabetes patients with obesity [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2022, 08(01): 30-35.

组　别	例数	PDGF		PGE2		TGF-β1
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	87	458.66±91.21	136.85±61.07^a	510.71±92.46	258.57±50.28^a	746.24±186.34	159.41±115.91^a
对照组	65	454.54±95.19	217.47±67.12^a	514.53±91.53	329.28±71.43^a	744.32±187.43	236.92±137.89^a
t值		0.270	7.717	0.253	7.162	0.0627	3.759
P值		0.787	0.000	0.800	0.000	0.950	0.000

组　别	例数	PDGF		PGE2		TGF-β1
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	87	458.66±91.21	136.85±61.07^a	510.71±92.46	258.57±50.28^a	746.24±186.34	159.41±115.91^a
对照组	65	454.54±95.19	217.47±67.12^a	514.53±91.53	329.28±71.43^a	744.32±187.43	236.92±137.89^a
t值		0.270	7.717	0.253	7.162	0.0627	3.759
P值		0.787	0.000	0.800	0.000	0.950	0.000

模态框（Modal）标题

Please choose a citation manager

Content to export

Influence of nintedanib on pulmonary function, pulmonary fibrosis degree and serum PDGF, PGE2 and TGF-β1 levels in patients with idiopathic pulmonary fibrosis

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 29

Related Articles 15

Recommended Articles

Metrics

Comments